JP2010536761A5 - - Google Patents

Download PDF

Info

Publication number
JP2010536761A5
JP2010536761A5 JP2010521050A JP2010521050A JP2010536761A5 JP 2010536761 A5 JP2010536761 A5 JP 2010536761A5 JP 2010521050 A JP2010521050 A JP 2010521050A JP 2010521050 A JP2010521050 A JP 2010521050A JP 2010536761 A5 JP2010536761 A5 JP 2010536761A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
solvate
stereoisomer
acceptable salt
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010521050A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010536761A (ja
JP5645663B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/009793 external-priority patent/WO2009023272A1/en
Publication of JP2010536761A publication Critical patent/JP2010536761A/ja
Publication of JP2010536761A5 publication Critical patent/JP2010536761A5/ja
Application granted granted Critical
Publication of JP5645663B2 publication Critical patent/JP5645663B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010521050A 2007-08-15 2008-08-15 ネクロトーシスのヘテロ環式抑制剤 Active JP5645663B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US95596607P 2007-08-15 2007-08-15
US60/955,966 2007-08-15
US3817508P 2008-03-20 2008-03-20
US61/038,175 2008-03-20
PCT/US2008/009793 WO2009023272A1 (en) 2007-08-15 2008-08-15 Heterocyclic inhibitors of necroptosis

Publications (3)

Publication Number Publication Date
JP2010536761A JP2010536761A (ja) 2010-12-02
JP2010536761A5 true JP2010536761A5 (OSRAM) 2011-09-29
JP5645663B2 JP5645663B2 (ja) 2014-12-24

Family

ID=40351022

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010521050A Active JP5645663B2 (ja) 2007-08-15 2008-08-15 ネクロトーシスのヘテロ環式抑制剤

Country Status (5)

Country Link
US (5) US20090099242A1 (OSRAM)
EP (2) EP3034494A1 (OSRAM)
JP (1) JP5645663B2 (OSRAM)
CA (1) CA2696349A1 (OSRAM)
WO (1) WO2009023272A1 (OSRAM)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2536622C (en) 2003-08-29 2014-02-11 The Brigham And Women's Hospital, Inc. Inhibitors of cellular necrosis
AU2006331754B9 (en) * 2005-12-20 2013-07-11 President And Fellows Of Harvard College Compounds, screens, and methods of treatment
AU2009329879A1 (en) 2008-12-23 2011-08-11 President And Fellows Of Harvard College Small molecule inhibitors of necroptosis
US20130137642A1 (en) 2010-04-23 2013-05-30 Demetrios Vavvas Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells
WO2011154826A1 (en) 2010-06-11 2011-12-15 Rhodes Technologies Process for n-dealkylation of tertiary amines
WO2011154827A2 (en) 2010-06-11 2011-12-15 Rhodes Technologies Transition metal-catalyzed processes for the preparation of n-allyl compounds and use thereof
US20140024598A1 (en) 2010-11-01 2014-01-23 Demetrios Vavvas Methods and compositions for preserving retinal ganglion cells
US9643977B2 (en) 2011-03-11 2017-05-09 President And Fellows Of Harvard College Necroptosis inhibitors and methods of use therefor
CA2888805C (en) 2011-10-21 2020-07-14 Massachusetts Eye And Ear Infirmary Methods and compositions for promoting axon regeneration and nerve function
TWI638815B (zh) 2013-02-15 2018-10-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類(一)
WO2014145022A1 (en) 2013-03-15 2014-09-18 President And Fellows Of Harvard College Hybrid necroptosis inhibitors
CN103535358B (zh) * 2013-10-18 2015-04-15 孙家隆 一组邻位取代苯甲酰化合物的杀菌剂用途
AR102981A1 (es) 2014-12-11 2017-04-05 Harvard College Inhibidores de la necrosis celular y métodos de preparación de los mismos
CN107108467B (zh) * 2014-12-24 2022-08-19 北京生命科学研究所 细胞坏死抑制剂
EP3224245B1 (en) 2014-12-24 2018-09-12 National Institute Of Biological Sciences, Beijing Necrosis inhibitors
IL247368A0 (en) 2016-08-18 2016-11-30 Yeda Res & Dev Diagnostic and therapeutic uses of exosomes
US10975064B2 (en) 2018-05-03 2021-04-13 Rigel Pharmaceuticals, Inc. RIP1 inhibitory compounds and methods for making and using the same
JP2021523226A (ja) 2018-05-03 2021-09-02 ライジェル ファーマシューティカルズ, インコーポレイテッド Rip1阻害剤化合物並びにそれを製造及び使用するための方法
CN113272272B (zh) 2018-11-20 2023-04-07 圣瑞诺有限公司 Rip1抑制剂
CN111978311B (zh) * 2019-05-21 2024-05-31 中国科学院上海有机化学研究所 一类细胞程序性坏死抑制剂及其制备方法和用途
BR112022002580A2 (pt) 2019-09-06 2022-07-19 Rigel Pharmaceuticals Inc Compostos inibitórios de rip1 e métodos para preparação e uso dos mesmos
PH12022550537A1 (en) 2019-09-06 2023-03-20 Rigel Pharmaceuticals Inc Rip1 inhibitory compounds and methods for making and using the same.
FI4055021T3 (fi) 2019-11-07 2025-12-16 Rigel Pharmaceuticals Inc Heterosyklisiä rip1:tä estäviä yhdisteitä
AR121717A1 (es) 2020-04-02 2022-06-29 Rigel Pharmaceuticals Inc Inhibidores de rip1k
EP4153582A4 (en) 2020-05-20 2024-06-19 Sironax Ltd. PIPERAZINE-TYPE CYCLIC UREAS
TWI824259B (zh) 2020-07-01 2023-12-01 美商雷傑製藥公司 Rip1k抑制劑
EP4247332A1 (en) * 2020-11-19 2023-09-27 Acousia Therapeutics GmbH Non-aqueous gel composition
TW202300490A (zh) 2021-03-11 2023-01-01 美商雷傑製藥公司 雜環rip1激酶抑制劑

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2728523C2 (de) 1977-06-23 1986-02-27 Schering AG, 1000 Berlin und 4709 Bergkamen 4-Methyl-1,2,3-thiadiazol-5-carbonsäure-(cyclohexylmethyl)-amid, Mittel mit herbizider und wachstumsregulatorischer Wirkung enthaltend diese Verbindung sowie Verfahren zu seiner Herstellung
US4356787A (en) 1977-12-30 1982-11-02 Harley Richard C Float construction
CA2268129C (en) * 1996-09-30 2003-03-11 Nihon Nohyaku Co., Ltd. 1,2,3-thiadiazole derivatives or salts thereof and agrohorticultural disease controller and method for using the same
JPH10152482A (ja) * 1996-09-30 1998-06-09 Nippon Nohyaku Co Ltd 1,2,3−チアジアゾール誘導体又はその塩類及び農園芸用病害防除剤ならびにその使用方法
PT957099E (pt) * 1998-04-15 2003-02-28 Pfizer Prod Inc Carboxamidas heterociclicas
EP0976326B1 (en) 1998-07-30 2003-05-02 Nihon Nohyaku Co., Ltd. Fungicidal composition containing a 1,2,3-tiadiazole derivative and its use
JP2000103710A (ja) * 1998-07-30 2000-04-11 Nippon Nohyaku Co Ltd 殺菌剤組成物及びその使用方法
US6756394B1 (en) * 1999-10-15 2004-06-29 President And Fellow Of Harvard College Small molecule inhibitors of necrosis
US6420400B1 (en) * 2000-04-07 2002-07-16 Kinetek Pharmaceuticals, Inc. Antiproliferative 1,2,3-thiadiazole compounds
DE60227655D1 (de) * 2001-04-19 2008-08-28 Dainippon Sumitomo Pharma Co Pyrrolderivat
DE10132686A1 (de) * 2001-07-05 2003-01-16 Boehringer Ingelheim Pharma Heteroarylcarbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
WO2003030937A1 (en) * 2001-10-05 2003-04-17 Ono Pharmaceutical Co., Ltd. Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists
ES2295553T3 (es) 2002-02-12 2008-04-16 Smithkline Beecham Corporation Derivados de nicotinamida utiles como inhibidores de p38.
DE10261131A1 (de) * 2002-12-20 2004-07-01 Grünenthal GmbH Substituierte 5-Aminomethyl-1H-pyrrol-2-carbonsäureamide
GB0302671D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
WO2005000821A1 (en) * 2003-06-12 2005-01-06 Eli Lilly And Company Tachykinin receptor antagonists
CA2536622C (en) * 2003-08-29 2014-02-11 The Brigham And Women's Hospital, Inc. Inhibitors of cellular necrosis
US7462612B2 (en) * 2004-03-26 2008-12-09 Vertex Pharmaceuticals Incorporated Pyridine inhibitors of ERK2 and uses thereof
SG155188A1 (en) * 2004-07-30 2009-09-30 Exelixis Inc Pyrrole derivatives as pharmaceutical agents
CN101163478B (zh) * 2005-01-25 2013-11-27 幸讬制药公司 用于炎症及免疫相关用途之化合物
KR101206317B1 (ko) * 2005-02-24 2012-11-29 니혼노야쿠가부시키가이샤 4-시클로프로필-1,2,3-티아디아졸 화합물 및 농원예용 식물병해 방제제 그리고 그 사용 방법
AU2006331754B9 (en) * 2005-12-20 2013-07-11 President And Fellows Of Harvard College Compounds, screens, and methods of treatment
JP2007186435A (ja) * 2006-01-12 2007-07-26 Astellas Pharma Inc ニコチンアミド誘導体
JP2009524677A (ja) * 2006-01-25 2009-07-02 シンタ ファーマシューティカルズ コーポレーション 炎症および免疫関連使用用のチアゾールおよびチアジアゾール化合物
PL1984338T3 (pl) * 2006-01-31 2013-06-28 Synta Pharmaceuticals Corp Związki pirydylofenylowe do zastosowań związanych z zapaleniami i odpornością
WO2007109362A2 (en) * 2006-03-20 2007-09-27 Synta Pharmaceuticals Corp. Benzoimidazolyl-parazine compounds for inflammation and immune-related uses
JP2009530409A (ja) * 2006-03-23 2009-08-27 シンタ ファーマシューティカルズ コーポレーション 炎症及び免疫関連使用用のベンゾイミダゾリル−ピリジン化合物
US20100087453A1 (en) 2006-10-10 2010-04-08 President And Fellows Of Harvard College Compounds, screens, and methods of treatment
JP5361857B2 (ja) 2007-03-23 2013-12-04 ファイザー・リミテッド イオンチャネルの阻害剤
WO2010075290A1 (en) 2008-12-22 2010-07-01 President And Fellows Of Harvard College Unsaturated heterocyclic inhibitors of necroptosis
AU2009329879A1 (en) 2008-12-23 2011-08-11 President And Fellows Of Harvard College Small molecule inhibitors of necroptosis

Similar Documents

Publication Publication Date Title
JP2010536761A5 (OSRAM)
JP5989660B2 (ja) 置換1−ベンジルシクロアルキルカルボン酸およびその使用
WO2016081649A1 (en) Thieno[2,3-d]pyrimidin-4-one derivatives as nmdar modulators and uses related thereto
WO2017048954A1 (en) Hepatitis b core protein modulators
JP2010522709A5 (OSRAM)
JP2008513496A5 (OSRAM)
WO2008054454A2 (en) Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents
JP2009542595A5 (OSRAM)
JP2011509252A (ja) 2−{4−[(3s)−ピペリジン−3−イル]フェニル}−2h−インダゾール−7−カルボキサミドの薬学的に許容される塩
JP2006528617A5 (OSRAM)
JP2015508092A5 (OSRAM)
JP2010522711A5 (OSRAM)
JP2010516702A5 (OSRAM)
JP2007527913A5 (OSRAM)
JP2010522710A5 (OSRAM)
JP2010504351A5 (OSRAM)
JP2025003530A (ja) アルドースレダクターゼの阻害剤
CN1136215C (zh) 异喹啉衍生物或其盐
WO2008113747A1 (en) Medicaments useful as potassium channel modulators
TWI555528B (zh) 泛醇基二十二碳六烯酸酯及其於治療與預防心血管疾病的用途
CN1225466C (zh) Ⅰ型钠-氢交换剂(nhe-1)抑制剂
JP2007521272A5 (OSRAM)
CN1164999A (zh) 苯并吡喃衍生物和将其作为有效成分的心脏病治疗药
CN1921855A (zh) 用于选择性增强心房收缩力以及治疗心功能不全的kv1.5-阻滞剂
AU2020216498A1 (en) Bicyclic pyridine compositions and methods of using the same for cancer therapy